Alnylam Pharmaceut (ALNY) 63.17 $ALNY
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
BusinessWire - Thu Jun 09, 7:00AM CDT
--- Company Expects to Present Initial Clinical Results in Late 2016 and to Initiate a Phase 3 Study in 2017 -
ALNY: 63.17 (-2.24)
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
BusinessWire - Fri Jun 03, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing Phase 1/2 study with ALN-CC5 in a webcast conference call on Saturday, June 11, 2016, at 8:30am ET. Results will be presented earlier that day in an oral presentation at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark.
ALNY: 63.17 (-2.24)
After Yesterday's Rally of 7.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 31, 3:43PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.21 to a high of $72.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $72.16 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.17 (-2.24)
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
BusinessWire - Tue May 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
ALNY: 63.17 (-2.24)
Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
Zacks Equity Research - Zacks Investment Research - Fri May 27, 9:45AM CDT
Ionis Pharmaceuticals' (IONS) shares touched a 52-week low after its partner Glaxo decided against starting a phase III outcome study CARDIO-TTR on IONIS-TTRRx.
ALNY: 63.17 (-2.24), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), IONS: 21.75 (+0.30)
Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:15AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) shares rose almost 10% in the last trading session.
ALNY: 63.17 (-2.24), ANIP: 52.05 (-1.64)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 1.98% Rise
Comtex SmarTrend(R) - Mon May 23, 3:47PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $54.53 to a high of $56.90. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $55.92 on volume of 256,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.17 (-2.24)
July 15th Options Now Available For Alnylam Pharmaceuticals (ALNY)
DividendChannel.com - Mon May 23, 10:37AM CDT
Investors in Alnylam Pharmaceuticals Inc saw new options begin trading today, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALNY options chain for the new July 15th contracts and...
ALNY: 63.17 (-2.24)
Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 1:12PM CDT
What: Alnylam Pharmaceuticals released earnings on Monday after the bell and fell 11.6% on Tuesday. Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in...
ALNY: 63.17 (-2.24), MDCO: 37.26 (-1.22), ALXN: 135.61 (-2.63)
Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:38AM CDT
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
ALNY: 63.17 (-2.24), GILD: 84.45 (-1.32), SNY: 39.41 (-1.45)
Alnylam reports 1Q loss
Automated Insights - Mon May 02, 3:11PM CDT
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Monday reported a loss of $103 million in its first quarter.
ALNY: 63.17 (-2.24)
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta
George Budwell, The Motley Fool - Motley Fool - Mon May 02, 3:10PM CDT
Not so long ago, Alnylam Pharmaceuticals and Sarepta Therapeutics were two of the hottest clinical-stage biotech stocks because of their emphasis on developing treatments for rare diseases. However, these two former stars have fallen on hard...
ALNY: 63.17 (-2.24), SRPT: 19.95 (-1.04)
Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
BusinessWire - Mon May 02, 3:00PM CDT
--- Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial in Late 2016 with Data Readout in Mid-2018 -
ALNY: 63.17 (-2.24)
Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
BusinessWire - Thu Apr 28, 6:00AM CDT
--- Facility Expected to be Operational in 2018 -
ALNY: 63.17 (-2.24)
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
BusinessWire - Tue Apr 26, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Deutsche Bank 41st Annual Health Care Conference on Wednesday, May 4, 2016 at 8:40 am ET at the InterContinental Hotel in Boston, Massachusetts, and at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at 10:00 am PT (1:00 pm ET) at the Encore at Wynn Las Vegas in Las Vegas, Nevada.
ALNY: 63.17 (-2.24), DB: 15.74 (-0.97)
Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results
BusinessWire - Mon Apr 25, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2016 on Monday, May 2, 2016, after the U.S. financial markets close.
ALNY: 63.17 (-2.24)
Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
BusinessWire - Wed Apr 20, 6:00AM CDT
--- Company Reports First-Ever Clinical Correlative Evidence that the Degree of TTR Knockdown May Be Associated with Improvement in mNIS+7 -
ALNY: 63.17 (-2.24)
Regeneron's Bold Bet on the Future of Medicine
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 2:03PM CDT
IMAGE SOURCE: REGENERON PHARMACEUTICALS, INC. Earlier this week, Regeneron Pharmaceuticals inked a collaboration deal with the privately held Intellia Therapeutics that could have moonshot implications in various disease indications. The...
ALNY: 63.17 (-2.24), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
[Podcast] Slingshot Insights and Estimize talk Biotech, Markets, and Forcerank
ESTMZ - Fri Apr 08, 10:42AM CDT
In case you missed it, check out the recording of yesterday’s webinar with Slingshot Insights! Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank....
BLUE: 41.59 (-3.92), BIIB: 246.13 (-4.33), ALNY: 63.17 (-2.24), KITE: 51.30 (-2.12), CELG: 102.91 (-3.22)
Alnylam Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 7.39%
Comtex SmarTrend(R) - Mon Apr 04, 2:56PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.62 to a high of $69.68. Yesterday, the shares gained 7.4%, which took the trading range above the 3-day high of $65.60 on volume of 695,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.17 (-2.24)
Alnylam Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an Investigational RNAi Therapeutic for the Treatment of TTR-Mediated Amyloidosis
BusinessWire - Thu Jun 09, 7:00AM CDT
--- Company Expects to Present Initial Clinical Results in Late 2016 and to Initiate a Phase 3 Study in 2017 -
ALNY: 63.17 (-2.24)
Alnylam to Webcast Conference Call Discussing ALN-CC5 Phase 1/2 Data
BusinessWire - Fri Jun 03, 7:00AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will discuss initial results in patients with paroxysmal nocturnal hemoglobinuria (PNH) from the ongoing Phase 1/2 study with ALN-CC5 in a webcast conference call on Saturday, June 11, 2016, at 8:30am ET. Results will be presented earlier that day in an oral presentation at the 21st Congress of the European Hematology Association (EHA) Meeting in Copenhagen, Denmark.
ALNY: 63.17 (-2.24)
After Yesterday's Rally of 7.00% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 31, 3:43PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $68.21 to a high of $72.39. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $72.16 on volume of 546,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.17 (-2.24)
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
BusinessWire - Tue May 31, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences:
ALNY: 63.17 (-2.24)
Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
Zacks Equity Research - Zacks Investment Research - Fri May 27, 9:45AM CDT
Ionis Pharmaceuticals' (IONS) shares touched a 52-week low after its partner Glaxo decided against starting a phase III outcome study CARDIO-TTR on IONIS-TTRRx.
ALNY: 63.17 (-2.24), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), IONS: 21.75 (+0.30)
Alnylam Pharmaceuticals (ALNY) in Focus: Stock Rises 9.9%
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:15AM CDT
Alnylam Pharmaceuticals, Inc. (ALNY) shares rose almost 10% in the last trading session.
ALNY: 63.17 (-2.24), ANIP: 52.05 (-1.64)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 1.98% Rise
Comtex SmarTrend(R) - Mon May 23, 3:47PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $54.53 to a high of $56.90. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $55.92 on volume of 256,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.17 (-2.24)
July 15th Options Now Available For Alnylam Pharmaceuticals (ALNY)
DividendChannel.com - Mon May 23, 10:37AM CDT
Investors in Alnylam Pharmaceuticals Inc saw new options begin trading today, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALNY options chain for the new July 15th contracts and...
ALNY: 63.17 (-2.24)
Alnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" Fall
Brian Orelli, The Motley Fool - Motley Fool - Wed May 04, 1:12PM CDT
What: Alnylam Pharmaceuticals released earnings on Monday after the bell and fell 11.6% on Tuesday. Of course, without any products on the market, the biotech's earnings don't really matter. But for the record, Alnylam recorded $7.3 million in...
ALNY: 63.17 (-2.24), MDCO: 37.26 (-1.22), ALXN: 135.61 (-2.63)
Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1
Zacks Equity Research - Zacks Investment Research - Tue May 03, 9:38AM CDT
Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.
ALNY: 63.17 (-2.24), GILD: 84.45 (-1.32), SNY: 39.41 (-1.45)
Alnylam reports 1Q loss
Automated Insights - Mon May 02, 3:11PM CDT
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Monday reported a loss of $103 million in its first quarter.
ALNY: 63.17 (-2.24)
Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta
George Budwell, The Motley Fool - Motley Fool - Mon May 02, 3:10PM CDT
Not so long ago, Alnylam Pharmaceuticals and Sarepta Therapeutics were two of the hottest clinical-stage biotech stocks because of their emphasis on developing treatments for rare diseases. However, these two former stars have fallen on hard...
ALNY: 63.17 (-2.24), SRPT: 19.95 (-1.04)
Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
BusinessWire - Mon May 02, 3:00PM CDT
--- Expects to Complete Enrollment of Revusiran Phase 3 ENDEAVOUR Trial in Late 2016 with Data Readout in Mid-2018 -
ALNY: 63.17 (-2.24)
Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
BusinessWire - Thu Apr 28, 6:00AM CDT
--- Facility Expected to be Operational in 2018 -
ALNY: 63.17 (-2.24)
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
BusinessWire - Tue Apr 26, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Deutsche Bank 41st Annual Health Care Conference on Wednesday, May 4, 2016 at 8:40 am ET at the InterContinental Hotel in Boston, Massachusetts, and at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at 10:00 am PT (1:00 pm ET) at the Encore at Wynn Las Vegas in Las Vegas, Nevada.
ALNY: 63.17 (-2.24), DB: 15.74 (-0.97)
Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results
BusinessWire - Mon Apr 25, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2016 on Monday, May 2, 2016, after the U.S. financial markets close.
ALNY: 63.17 (-2.24)
Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
BusinessWire - Wed Apr 20, 6:00AM CDT
--- Company Reports First-Ever Clinical Correlative Evidence that the Degree of TTR Knockdown May Be Associated with Improvement in mNIS+7 -
ALNY: 63.17 (-2.24)
Regeneron's Bold Bet on the Future of Medicine
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 12, 2:03PM CDT
IMAGE SOURCE: REGENERON PHARMACEUTICALS, INC. Earlier this week, Regeneron Pharmaceuticals inked a collaboration deal with the privately held Intellia Therapeutics that could have moonshot implications in various disease indications. The...
ALNY: 63.17 (-2.24), SNY: 39.41 (-1.45), REGN: 372.03 (-9.05)
[Podcast] Slingshot Insights and Estimize talk Biotech, Markets, and Forcerank
ESTMZ - Fri Apr 08, 10:42AM CDT
In case you missed it, check out the recording of yesterday’s webinar with Slingshot Insights! Leigh Drogen, Founder of Estimize, joins Joe McCann of Slingshot Insights to talk Biotech stocks, the market, and his latest creation ForceRank....
BLUE: 41.59 (-3.92), BIIB: 246.13 (-4.33), ALNY: 63.17 (-2.24), KITE: 51.30 (-2.12), CELG: 102.91 (-3.22)
Alnylam Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 7.39%
Comtex SmarTrend(R) - Mon Apr 04, 2:56PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $64.62 to a high of $69.68. Yesterday, the shares gained 7.4%, which took the trading range above the 3-day high of $65.60 on volume of 695,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ALNY: 63.17 (-2.24)
